Alaunos Therapeutics (Alaunos Therapeutics) Short-Term Debt & Capital Lease Obligation

: $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Alaunos Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Alaunos Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.

Alaunos Therapeutics Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Alaunos Therapeutics's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alaunos Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

0.77

0.82

8.60

17.32

Alaunos Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt & Capital Lease Obligation																17.32	11.56	0.34	0.31	-

Alaunos Therapeutics Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Alaunos Therapeutics Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Alaunos Therapeutics's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Alaunos Therapeutics (Alaunos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (NAS:TCRT) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

8030 El Rio Street, Houston, TX, USA, 77054

Website

https://www.alaunos.com

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.

Executives

Boyle Kevin S. Sr.	director, officer: Chief Executive Officer	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Robert Hofmeister	director	C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Jaime Vieser	director	ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON MA 02129
Robert W Postma	director	141 MECOX ROAD, WATER MILL NY 11976
Michael Wong	officer: VP, Finance	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Abhishek K Srivastava	officer: See Remarks	C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Holger Weis	director	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Christopher Bowden	director	38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Mary Thistle	director	C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
James Huang	director	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Drew Deniger	officer: VP, Research & Development	C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Groot Eleanor De	officer: EVP, Operations	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Melinda Lackey	officer: Senior Vice President, Legal	C/O ZIOPHARM ONCOLOGY INC., 8030 EL RIO ST, HOUSTON TX 77054
Heidi Hagen	director	AASTROM BIOSCIENCES, INC., 24 FRANK LLOYD WRIGHT DRIVE, ANN ARBOR MI 48105
Raffaele Baffa	officer: Chief Medical Officer	C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129